-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Zentalis Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2019 to Q2 2024.
- Zentalis Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$65.1M, a 37.3% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$221M, a 19.7% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$300M, a 31.8% decline from 2022.
- Zentalis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$227M, a 4.96% decline from 2021.
- Zentalis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$217M, a 82.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)